

Title	Predict and Prevent - Reducing CVD events by Optimising Cholesterol Management for High Risk Patients in the North West Coast Region
Organisations Involved	Amgen Ltd and Innovation Agency AHSN
Joint Working Project Description	<p>The Project was designed to support the delivery of the NHS CVD aspect of the Long-Term Plan. The focus was to improve cholesterol management in high risk patients one of the CVD modifiable risk factors, to within parameters set by NICE guidelines with a focus on three areas:</p> <ol style="list-style-type: none"> 1. Support the clinical priority to reduce the number of CVD events. 2. Use of population health analysis to identify cohorts of patients who are most in need of an intervention. 3. Ensure where appropriate, interventions are conducted in primary care by MDT teams within a primary care network ("PCN") footprint and not by Secondary Care.
Expected Outcomes	<ul style="list-style-type: none"> • Standardised searches developed for Primary Care IT systems to identify high-risk CVD patient cohorts if CVD Prevent NHS tool is not available. • Patients identified from the searches to be reviewed by Primary Care Team and improvements in lipid control monitored at 6 & 12 months by either point of care testing or blood tests. • Implementation of revised lipid protocols and improved local pathways between Primary and Secondary Care Teams within participating practices. • Delivery of education and quality improvement training to practices in partnership with relevant colleagues across the pathway such as secondary care teams, social prescribers, and CCG medical optimisation team to increased confidence in lipid management across the primary care workforce. • Increased uptake of second-line therapies in line with NICE guidance. • Completed evaluation of project. • Using non identifiable data identified by the project, to develop a population health focused business case for sustainability and rollout of the search and optimise process across the local healthcare system. • Share business case across NHS systems.
Actual Outcomes	<ul style="list-style-type: none"> • Across the 2 ICS regions in the NWC, lipid and FH referral pathways and management guidance were revised and implemented to include new National NICE approved guidance as part of the project. • Both locally designed and nationally available (UCLP Partners and CDRC) search and stratification tools used to identify patients requiring lipid review, optimisation, or referral in line with the

	<p>Primary/Secondary Prevention/FH pathway national guidance, provided by the Accelerated Access Collaborative Team.</p> <ul style="list-style-type: none">• 4 workstreams, 2 focussed on secondary prevention and 2 on Familial Hypercholesterolaemia were delivered across 8 PCNs within the NWC region.• Positive changes such as increased use of high-intensity statins and an increase in the number of patients treated to the NICE target for LDL were observed in all of the patient cohorts.• Increased uptake of second-line therapies in line with NICE guidance.• Improvements were seen in FH coding, FH patient identification and management of those patients.• A number of learnings regarding patient motivation, how to improve the % of DNA sessions in clinics and how focussing on better patient education and awareness of the effect lipids can have on CVD, were captured, and documented to support the enhancement and continuing development of local pathways and a summary is available in the final evaluation report.• Participation in the project by a broad range of HCPs increased the competence and confidence of healthcare professionals in managing lipid-related issues, addressing statin hesitancy, and improving patient outcomes.• Data from the project has supported local business cases for further funding in parts of the NWC but, as of yet, there is no specific tool developed across England, that can forecast a return on investment for supporting activity optimising lipids due to the variance in baseline data and incorrect coding of lipid related issues.• The Innovation Agency commissioned an evaluation of this project. The report is available.
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GBR-NP-0225-80018 February 2025